跳至主要内容
临床试验/NCT03613311
NCT03613311已完成不适用

Prevalence Rates of Evident, Occult and no Demonstrated Urodynamic Stress Incontinence and Their Clinical and Urodynamic Findings in Women With ≥Stage II Cystocele

National Taiwan University Hospital0 个研究点目标入组 480 人开始时间: 2011年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
480
主要终点
Evident USI

研究概览

简要总结

Prevalence rates of urodynamic urinary incontinence (USI) subtypes and their related clinical and urodynamic findings in women with ≥ pelvic organ prolapse quantification stage II cystocele are important for clinical consultation, especially for occult USI. Misdiagnosis of occult USI before cystocele repair might lead to occurrence of de novo stress urinary incontinence after cystocele repair. Thus, the aim of this study was to elucidate the above findings and between-group associations.

详细描述

Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. ANOVA test and post-hoc testing with bonferroni's correction were used for statistical analysis. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction. The recruited patients with cystocele were classified into three groups (i.e.,evident USI, occult USI and no demonstrated USI) according to pad weight results before and after prolapse reduction.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age >20y/o
  • Cystocele > stage II
  • Complete urodynamic study

排除标准

  • Urinary tract infection
  • Previous pelvic reconstruction surgery

结局指标

主要结局

Evident USI

时间窗: Between November 2011 and January 2017

USI note before reduction of prolapse

Occult USI

时间窗: Between November 2011 and January 2017

USI note after reduction of prolapse

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Evident, Occult and no Demonstrated USI and UDS... | 临床试验